Business Description
Lincoln Pharmaceuticals Ltd
ISIN : INE405C01035
Compare
Compare
Traded in other countries / regions
LINCOLN.India IPO Date
2000-11-27Description
Lincoln Pharmaceuticals Ltd is an India-based company engaged in the business of manufacturing and trading of pharmaceutical products. It offers products in the fields of Cardiac, Diabetic, Anti-malarial, Anti-biotic, Anti-fungal, Cephalosporin, Analgesic, Anaesthetics, Anti-pyretic, GIT products, Vitamin-Minerals, and Iron preparations. Geographically, the company carries out sales in India and outside India; generating key revenue from outside India.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 195.62 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-EBITDA | 0.01 | |||||
| Interest Coverage | 41.54 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.15 | |||||
| Beneish M-Score | -1.55 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | 13.6 | |||||
| 3-Year EPS without NRI Growth Rate | 11.8 | |||||
| 3-Year FCF Growth Rate | -28.3 | |||||
| 3-Year Book Growth Rate | 17 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 11.82 | |||||
| 9-Day RSI | 23.21 | |||||
| 14-Day RSI | 30.77 | |||||
| 6-1 Month Momentum % | 10.52 | |||||
| 12-1 Month Momentum % | 60.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.25 | |||||
| Quick Ratio | 3.62 | |||||
| Cash Ratio | 1.7 | |||||
| Days Inventory | 102.98 | |||||
| Days Sales Outstanding | 106.81 | |||||
| Days Payable | 102.5 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.26 | |||||
| Dividend Payout Ratio | 0.03 | |||||
| 3-Year Dividend Growth Rate | -20.6 | |||||
| Forward Dividend Yield % | 0.26 | |||||
| 5-Year Yield-on-Cost % | 0.26 | |||||
| Shareholder Yield % | 0.71 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54 | |||||
| Operating Margin % | 15.95 | |||||
| Net Margin % | 15.85 | |||||
| FCF Margin % | 4.54 | |||||
| ROE % | 17.26 | |||||
| ROA % | 14.12 | |||||
| ROIC % | 16.39 | |||||
| ROC (Joel Greenblatt) % | 39.18 | |||||
| ROCE % | 22.98 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.5 | |||||
| PE Ratio without NRI | 13.5 | |||||
| Shiller PE Ratio | 19.81 | |||||
| Price-to-Owner-Earnings | 30.06 | |||||
| PEG Ratio | 0.94 | |||||
| PS Ratio | 2.14 | |||||
| PB Ratio | 2.16 | |||||
| Price-to-Tangible-Book | 2.03 | |||||
| Price-to-Free-Cash-Flow | 47.17 | |||||
| Price-to-Operating-Cash-Flow | 30.02 | |||||
| EV-to-EBIT | 7.81 | |||||
| EV-to-EBITDA | 7.19 | |||||
| EV-to-Revenue | 1.7 | |||||
| EV-to-FCF | 40.89 | |||||
| Price-to-Projected-FCF | 1.33 | |||||
| Price-to-DCF (Earnings Based) | 0.53 | |||||
| Price-to-DCF (FCF Based) | 4.77 | |||||
| Price-to-Median-PS-Value | 1.89 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.96 | |||||
| Price-to-Graham-Number | 1.11 | |||||
| Price-to-Net-Current-Asset-Value | 3.44 | |||||
| Price-to-Net-Cash | 18.99 | |||||
| Earnings Yield (Greenblatt) % | 12.81 | |||||
| FCF Yield % | 2.26 | |||||
| Forward Rate of Return (Yacktman) % | 17.72 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lincoln Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 5,505.162 | ||
| EPS (TTM) (₹) | 43.58 | ||
| Beta | 0.54 | ||
| Volatility % | 45.48 | ||
| 14-Day RSI | 30.77 | ||
| 14-Day ATR (₹) | 21.83925 | ||
| 20-Day SMA (₹) | 590.405 | ||
| 12-1 Month Momentum % | 60.59 | ||
| 52-Week Range (₹) | 365.4 - 754.25 | ||
| Shares Outstanding (Mil) | 20.03 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lincoln Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lincoln Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lincoln Pharmaceuticals Ltd Frequently Asked Questions
What is Lincoln Pharmaceuticals Ltd(BOM:531633)'s stock price today?
The current price of BOM:531633 is ₹551.90. The 52 week high of BOM:531633 is ₹754.25 and 52 week low is ₹365.40.
When is next earnings date of Lincoln Pharmaceuticals Ltd(BOM:531633)?
The next earnings date of Lincoln Pharmaceuticals Ltd(BOM:531633) is .
Does Lincoln Pharmaceuticals Ltd(BOM:531633) pay dividends? If so, how much?
The Dividend Yield %  of Lincoln Pharmaceuticals Ltd(BOM:531633) is 0.26% (As of Today), Highest Dividend Payout Ratio of Lincoln Pharmaceuticals Ltd(BOM:531633) was 0.12. The lowest was 0.03. And the median was 0.07. The  Forward Dividend Yield % of Lincoln Pharmaceuticals Ltd(BOM:531633) is 0.26%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers